129 related articles for article (PubMed ID: 36369821)
41. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
[TBL] [Abstract][Full Text] [Related]
42. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2014 May; 89(5):547-56. PubMed ID: 24729196
[TBL] [Abstract][Full Text] [Related]
43. Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.
Etienne G; Huguet F; Guerci-Bresler A; Nicolini FE; Maloisel F; Coiteux V; Dauriac C; Carpentier N; Bourdeix I; Tulliez M; Cony-Makhoul P
Br J Haematol; 2016 Jul; 174(1):71-80. PubMed ID: 27060881
[TBL] [Abstract][Full Text] [Related]
44. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.
Valent P; Lion T; Wolf D; Sillaber C; Agis H; Petzer A; Lang A; Kalhs P; Geissler D; Greil R; Linkesch W; Burgstaller S; Thaler J; Gastl G
Wien Klin Wochenschr; 2008; 120(21-22):697-709. PubMed ID: 19116712
[TBL] [Abstract][Full Text] [Related]
46. [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
Meng FY; Zheng WY; Liu XL; Xu B; Song LL; Zhang Y; Huang F
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1149-50. PubMed ID: 14625174
[TBL] [Abstract][Full Text] [Related]
47. Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry.
Meral Günes A; Millot F; Kalwak K; Lausen B; Sedlacek P; Versluys AB; Dworzak M; De Moerloose B; Suttorp M
Pediatr Blood Cancer; 2021 Jan; 68(1):e28706. PubMed ID: 33034135
[TBL] [Abstract][Full Text] [Related]
48. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
Maas CCHM; van Klaveren D; Ector GICG; Posthuma EFM; Visser O; Westerweel PE; Janssen JJWM; Blijlevens NMA; Dinmohamed AG
Br J Haematol; 2022 Mar; 196(5):1219-1224. PubMed ID: 34865221
[TBL] [Abstract][Full Text] [Related]
49. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
[TBL] [Abstract][Full Text] [Related]
50. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
[TBL] [Abstract][Full Text] [Related]
51. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480
[TBL] [Abstract][Full Text] [Related]
52. Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.
Ahmed R; Singh R; Kapoor J; Chandra Patra P; Agrawal N; Bhurani D; Halder R
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e71-e77. PubMed ID: 36566108
[TBL] [Abstract][Full Text] [Related]
53. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
[TBL] [Abstract][Full Text] [Related]
54. Adherence to Monitoring Tests in Patients With Chronic Myeloid Leukemia in Lebanon.
Massoud M; Nasr F; Sakr R; Hawi J; Kerbage F; Chahine G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S101-4. PubMed ID: 27220473
[TBL] [Abstract][Full Text] [Related]
55. Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia.
Seo HY; Ko TH; Hyun SY; Song H; Lim ST; Shim KY; Lee JI; Kong JH
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):735-743.e2. PubMed ID: 31563565
[TBL] [Abstract][Full Text] [Related]
56. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.
Nicolini FE; Etienne G; Dubruille V; Roy L; Huguet F; Legros L; Giraudier S; Coiteux V; Guerci-Bresler A; Lenain P; Cony-Makhoul P; Gardembas M; Hermet E; Rousselot P; Amé S; Gagnieu MC; Pivot C; Hayette S; Maguer-Satta V; Etienne M; Dulucq S; Rea D; Mahon FX
Lancet Haematol; 2015 Jan; 2(1):e37-46. PubMed ID: 26687426
[TBL] [Abstract][Full Text] [Related]
57. The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach.
Ector GI; Westerweel PE; Hermens RP; Braspenning KA; Heeren BC; Vinck OM; de Jong JJ; Janssen JJ; Blijlevens NM
J Med Internet Res; 2020 May; 22(5):e15895. PubMed ID: 32412424
[TBL] [Abstract][Full Text] [Related]
58. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
Hoffmann VS; Baccarani M; Hasford J; Castagnetti F; Di Raimondo F; Casado LF; Turkina A; Zackova D; Ossenkoppele G; Zaritskey A; Höglund M; Simonsson B; Indrak K; Sninska Z; Sacha T; Clark R; Bogdanovic A; Hellmann A; Griskevicius L; Schubert-Fritschle G; Sertic D; Guilhot J; Lejniece S; Zupan I; Burgstaller S; Koskenvesa P; Everaus H; Costeas P; Lindoerfer D; Rosti G; Saussele S; Hochhaus A; Hehlmann R
Leukemia; 2017 Mar; 31(3):593-601. PubMed ID: 27568522
[TBL] [Abstract][Full Text] [Related]
59. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis.
Selleri C; Maciejewski JP; Pane F; Luciano L; Raiola AM; Mostarda I; Salvatore F; Rotoli B
Blood; 1998 Aug; 92(3):981-9. PubMed ID: 9680367
[TBL] [Abstract][Full Text] [Related]
60. BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.
Paramita DK; Hutajulu SH; Syifarahmah A; Sholika TA; Fatmawati S; Aning S; Sulistyawati D; Wahyuni S; Taroeno-Hariadi KW; Kurnianda J
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1545-1550. PubMed ID: 32592347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
